China will refine its drug pricing system with 14 measures, according to a State
Council document released on Apr 14, Xinhua reported.
Key steps include optimizing launch pricing for innovative and newly listed
drugs, leveraging醫保 payment standards to guide pricing, and encouraging
pharmacies to set reasonable retail prices, while strengthening supply and price
stability for shortage medicines.
The plan also calls for enhanced governance, including price risk monitoring and
early-warning systems, stricter enforcement against manipulation, full-chain
audit oversight, and a drug value assessment system, aiming to keep prices
within a reasonable range.
